Atossa Therapeutics (ATOS) Stock Is About To Hit New Highs: How to Trade?

Over the course of the past six weeks, the Atossa Therapeutics (NASDAQ:ATOS) stock...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


Inspira Technologies IINN is Up, Why is That? Take a...
NMRD Stock: Why is Nemaura Medical (NASDAQ: NMRD) A ...

Over the course of the past six weeks, the Atossa Therapeutics (NASDAQ:ATOS) stock has been in the middle of a strong rally and during that period, it managed to deliver gains of as much as 160%.

The Atossa stock kicked off the month of June on a strong note as well and clocked gains of as much as 20% yesterday. There was no announcement from the company yesterday but an analyst actually raised his price target for the Atossa stock and that seems to have come as a major trigger for the rally in the stock. Hence, it might be a good idea now for investors to take a closer look at the stock.

In a new development, analyst Edward Woo raised the target price for the Atossa stock from $7.75 a share to $8 a share. However, it should be noted that the new target price is just more than double the previous closing price of the stock. On the other hand, Woo maintained the buy rating on the stock.

One of the biggest reasons behind the bullish sentiments about the Atossa stocks is its oral breast cancer product named Endoxifen. Breast cancer is a widespread disease and it is believed that Endoxifen could eventually add substantially to the company’s revenues.

Back in February, Atossa also conducted a phase 2 clinical study of the product in Australia and announced that the results were ‘overwhelmingly positive’. The comment was in relation to the effectiveness of the product in reducing the activity of tumour cells.

In addition to that, the company has also managed to come up with two medications that are meant to treat patients suffering from COVID 19. In this regard it is also important to note that Woo has been bullish about the stock for quite some time and had given a buy rating to Atossa in September last year.

Stay in the lopp :

NuGene NUGN Stock Price is down 47%, can it g...

NuGene NUGN stock price is down 47% in the last 5 days & volume is down too -18%, but is it

PIK Stock Price is ready for another run? URG...

Kidpik Corp. PIK Stock Price has been taking a beating for a while but in the last month it has reversed trend. To

DatChat NASDAQ: DATS breakout?

DatChat NASDAQ: DATS is down 10% today and we are patiently waiting for a signal of a reversal. Let's take a close look

related post

Skip to content